Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Getting risks right on inhaled corticosteroids and adrenal insufficiency

Laura Watkins, Joan B. Soriano, Kevin Mortimer
European Respiratory Journal 2013 42: 9-11; DOI: 10.1183/09031936.00204212
Laura Watkins
1Thoracic Medicine, University Hospital Aintree, Liverpool
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan B. Soriano
2Epidemiology and Clinical Research, CIMERA, Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Mortimer
1Thoracic Medicine, University Hospital Aintree, Liverpool
3School of Tropical Medicine, University of Liverpool, Liverpool, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: laura.watkins@nhs.net
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

As Thomas Addison observed in his famous monograph written in 1855, the adrenal glands are “objects of deep interest” and so they remain [1]. In the monograph he described several patients who presented with generalised weakness and in whom abnormalities of the adrenal glands were found at post mortem. Addison had discovered primary hypoadrenalism, the disease that would later take his name. He observed that “the disease is by no means of very rare occurrence, and that were we better acquainted with its symptoms and progress, we should probably succeed in detecting many cases” [1].

With Addison's words ringing in our ears we reflect on the paper by Lapi et al. [2] in this issue of the European Respiratory Journal. Lapi et al. [2] describe a nested case–control study examining the association between inhaled corticosteroids and adrenal insufficiency conducted within a cohort of patients treated for respiratory conditions over a 15-year period, starting in 1990, in Quebec, Canada. They identified 392 cases of adrenal insufficiency from 368 238 prevalent users of respiratory medicines from the Régie de l'assurance médicale du Québec database. They did not find, as per their primary objective, an increased risk of adrenal insufficiency among current users of inhaled corticosteroids. However, they did report an increased risk in relation to the use of a current high dose (≥=2000 μg beclomethasone dipropionate (BDP)–units per day, equivalent to 1000 μg fluticasone per day) of inhaled corticosteroids (OR=1.84; 95% CI: 1.16–2.90). They concluded that high doses of inhaled corticosteroids are an independent risk factor for adrenal insufficiency although the risk was much smaller than that seen with oral corticosteroids.

This study provides interesting new data, and will add fuel to the debate, about the risk of adrenal insufficiency in patients prescribed inhaled corticosteroids. In our view the conclusion that high doses of inhaled corticosteroids alone increase the risk of adrenal insufficiency is not fully supported by the data presented. Although cases were more likely than controls to be users of high doses of inhaled corticosteroids, the lack of a clear dose–response relationship across the three tertiles of cumulative inhaled corticosteroid dose in the current users and, if anything, the protective effect of recent or past use, as depicted in table 2, casts some doubt on the assertion that there is an independent dose-related impact of inhaled corticosteroids on adrenal insufficiency. A critical issue overall is the overwhelming influence of oral corticosteroid therapy; there was an order of magnitude difference in the cumulative dose of oral corticosteroids in cases versus controls (547.4 mg versus 42.5 mg). Although the authors adjusted for the effect of oral corticosteroids, it is a difficult task to completely adjust for these strong effects. Residual confounding by systemic corticosteroids is likely to be substantial and quite possibly sufficient to explain the apparent association between inhaled corticosteroids and adrenal insufficiency in this study.

In an earlier case–control study looking at oral and inhaled corticosteroids and adrenal insufficiency, Mortimer et al. [3] compared 154 cases of adrenal insufficiency and 870 controls from a UK primary care database. They found a dose-related increased risk of adrenal insufficiency in people prescribed oral (OR 2.0; 95% CI 1.6–2.5 per course of treatment per year) or inhaled corticosteroids (OR 3.4; 95% CI 1.9–5.9 for a prescription for inhaled corticosteroids during the 90 days before the diagnosis), but the inhaled corticosteroid effect was essentially lost after adjustment for oral corticosteroid exposure. Whilst an effect of inhaled corticosteroids was not excluded, the dominant effect on adrenal insufficiency was explained by oral corticosteroid use.

Nevertheless, cases of adrenal insufficiency in patients taking inhaled corticosteroids continue to be seen in clinical practice and reported [4–8]. Many have been in children taking particularly high doses of an inhaled corticosteroid, often fluticasone. For example, Denne et al. [7] recently described a case of adrenal insufficiency attributed to fluticasone in an adolescent patient with cystic fibrosis and associated hepatic cirrhosis. Cases such as this emphasise the role comorbidities and interacting drugs can play in influencing the risk. This helps to illustrate that some individual patients do indeed appear to develop adrenal insufficiency from inhaled corticosteroid use.

It is now well established that inhaled corticosteroids are absorbed into the systemic circulation, that their absorption is affected by lung function and that measureable dose-related systemic biological effects can occur [9–13]. Taken together with other data including the case reports and case–control studies, there is indeed evidence that inhaled corticosteroid use is associated with adrenal insufficiency, although the absolute risk is low and the association is dominated by the effects of systemic corticosteroid therapy. Patients taking especially high doses of inhaled corticosteroids are also likely to have had high cumulative doses of oral corticosteroids and will be the group of patients at greatest risk of adrenal insufficiency.

The message we take from the paper by Lapi et al. [2] is that adrenal insufficiency remains the “unforgiving master of nonspecificity and disguise” [14] and should be considered in patients taking inhaled corticosteroids presenting with suggestive symptoms, irrespective of whether or not the inhaled corticosteroid was the original culprit. Since iatrogenic secondary adrenal insufficiency does not impair mineralocorticoid- or melanocyte-stimulating hormone secretion it is unlikely that electrolyte disturbance or hyperpigmentation, respectively, will be present and so the presentation may be all the more unforgiving, nonspecific and disguised [8, 15]. 150 years after Addison, adrenal suppression in asthma remains a serious but rare event; its occurrence, determinants and screening remains a subject of ongoing debate [16]. Getting the risks right is a continuous endeavour of pharmacovigilance and pharmacoepidemiology [17], with the intention to protect our patients.

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

  • Received December 18, 2012.
  • Accepted January 2, 2013.
  • ©ERS 2013

References

  1. ↵
    1. Addison T
    . On the constitutional and local effects of the disease of the supra-renal capsules. In: Wilks S, Daldy TM , eds. A Collection of the Published Writings of the Late Thomas Addison MD. London, New Sydenham Society, 1868; pp. 211–239.
  2. ↵
    1. Lapi F,
    2. Kezouh A,
    3. Suissa S,
    4. et al
    . The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J 2013; 42: 79–86.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Mortimer KJ,
    2. Tata LJ,
    3. Smith CJ,
    4. et al
    . Oral and inhaled corticosteroids and adrenal insufficiency: a case–control study. Thorax 2006; 61: 405–408.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Todd GR,
    2. Acerini CL,
    3. Ross-Russell R,
    4. et al
    . Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457–461.
    OpenUrlAbstract/FREE Full Text
    1. Todd GR
    . Adrenal crisis due to inhaled steroids is underestimated. Arch Dis Child 2003; 88: 554–555.
    OpenUrlFREE Full Text
    1. Mydin HH
    . Case history: a case of adrenal insufficiency secondary to symbicort. InnovAiT 2010; 3: 182–183.
    OpenUrlFREE Full Text
  5. ↵
    1. Denne C,
    2. Vogl-Voswinckel AE,
    3. Gruebl A,
    4. et al
    . Adrenal crisis caused by inhaled fluticasone in an adolescent with cystic fibrosis and advanced hepatopathy: a case report. Case Rep Pulmonol 2012; 2012: 913574.
    OpenUrlPubMed
  6. ↵
    1. Schwatz RH,
    2. Neacsu O,
    3. Ascher DP,
    4. et al
    . Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. Clin Pediatr (Phila) 2012; 51: 1184–1190.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Brutsche MH,
    2. Brutsche IC,
    3. Munawar M,
    4. et al
    . Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556–561.
    OpenUrlCrossRefPubMedWeb of Science
    1. Harrison TW,
    2. Tattersfield AE
    . Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58: 258–260.
    OpenUrlAbstract/FREE Full Text
    1. Mortimer KJ,
    2. Harrison TW,
    3. Tang Y,
    4. et al
    . Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 2006; 62: 412–419.
    OpenUrlCrossRefPubMedWeb of Science
    1. Donnelly R,
    2. Williams KM,
    3. Baker AB,
    4. et al
    . Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose–response study. Am J Respir Crit Care Med 1997; 156: 1746–1751.
    OpenUrlPubMedWeb of Science
  8. ↵
    1. Weiner P,
    2. Berar-Yanay N,
    3. Davidovich A,
    4. et al
    . Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116: 931–934.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Brosnan CM,
    2. Gowing NF
    . Addison's disease. BMJ 1996; 312: 1085–1087.
    OpenUrlFREE Full Text
  10. ↵
    1. Shulman DI,
    2. Palmert MR,
    3. Kemp SF,
    4. et al
    . Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics 2007; 199: e484–e494.
    OpenUrl
  11. ↵
    1. Brodlie M,
    2. McKean MC
    . Strategies to screen for adrenal suppression in children with asthma: there is no consensus among UK centres. Thorax 2008; 63: 841–842.
    OpenUrlFREE Full Text
  12. ↵
    1. Avorn J
    . Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, Alfred A. Knopf, 2004.
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 1 Table of Contents
European Respiratory Journal: 42 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Getting risks right on inhaled corticosteroids and adrenal insufficiency
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Getting risks right on inhaled corticosteroids and adrenal insufficiency
Laura Watkins, Joan B. Soriano, Kevin Mortimer
European Respiratory Journal Jul 2013, 42 (1) 9-11; DOI: 10.1183/09031936.00204212

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Getting risks right on inhaled corticosteroids and adrenal insufficiency
Laura Watkins, Joan B. Soriano, Kevin Mortimer
European Respiratory Journal Jul 2013, 42 (1) 9-11; DOI: 10.1183/09031936.00204212
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Commemorating World Tuberculosis Day 2022
  • Is low level of vitamin D a marker of poor health or its cause?
  • Risky political game with climate change
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society